@charlesrudin Dr. Charlie Rudin presenting positive overall survival results for tarlatamab in previously treated small cell lung cancer compared to 2nd line chemotherapy. #ASCO2025 @MSKCancerCenter
Mark Awad
@DrMarkAwad
Chief, Thoracic Oncology, Memorial Sloan Kettering Cancer Center @MSKCancerCenter | Lung Cancer Immunotherapy Research | Tweets my own
489 Following 2.8K Followers 206 Posts
Latest posts 5
Congratulations to Dr. Jamie Chaft @ChaftJamie and co-investigators on the NeoADAURA clinical trial of neoadjuvant osimertinib in EGFR mutant lung cancer. #ASCO25 @EGFRResisters @MSKCancerCenter
Wonderful presentation from Dr. Alissa Cooper @alissajcooper on SEZ6 ADC ABBV-706 showing efficacy in diverse neuroendocrine tumors @MSKCancerCenter
Congratulations to Charlie Rudin & DeLLphi-304 investigators on this practice-changing trial for our patients with small cell lung cancer @MSKCancerCenter
Tarlatamab in SCLC after Platinum-Based Chemotherapy | New England Journal of Medicine nejm.org/doi/full/10.10…
www.nejm.org Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | NEJM Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Wheth... Tarlatamab in SCLC after Platinum-Based Chemotherapy | New England Journal of Medicine nejm.org/doi/full/10.10…
Congratulations to Kathryn Arbour @KCArbourMD and colleagues showing activity of BMS-986504 in MTAP-deleted solid tumors, including lung and pancreas cancer. @MSKCancerCenter
